Lung cancer is the leading cause of cancer-related death worldwide, exceeding that attributable to breast, prostate, colon, kidney, and liver cancer combined. Recently, the identification of recurrent genetic alterations has led to molecularly-targeted therapies for a subset of lung cancers. Activating mutations in RAS-family oncoproteins are among the most frequent genomic alterations in non-small cell lung cancer (NSCLC) and are mutated in up to 30% of all human cancers. Despite intensive efforts to target KRAS, no molecularly targeted therapies exist and patients still receive cytotoxic and largely ineffective chemotherapies. Indeed, direct pharmacological inhibition of mutant RAS has remained difficult, and targeting of other downstream RAS effectors, in particular the MAPK pathway, has been ineffective due to toxicities and adaptive drug resistance mechanisms. In response to the urgent need for developing strategies to target KRAS mutant cancers, this Program Project has explored that action of agents that target the RAS network, producing insights into adaptive resistance mechanisms and characterizing the first direct KRAS mutant inhibitors. Our project, together with Rosen (RP2), established that the rebound in MAPK signaling occurring after MEK inhibition is responsible for adaptive drug resistance and, though a functional genomics screen, identified upstream activation of the FGFR1 signaling axis as contributing to this effect. Consequently, FGFR1 is an induced dependency produced by MEK inhibition and therapeutic approaches targeting MEK and FGFR1 are being developed as a clinical strategy for treating KRAS mutant lung cancers. Our renewal builds on these successes towards the goal of identifying additional combinatorial strategies targeting KRAS mutant cancers. Expanding upon extensive preliminary data, we study effectors required for tumor maintenance in KRAS driven lung cancers treated with MAPK or KRAS inhibitors, explore novel and existing strategies for combinatorial target inhibition, and examine the interplay between pathway inhibition, tissue and genomic context, and immune surveillance. The project builds on existing collaborations and incorporates innovative technology and mouse modeling systems into the program; it interacts with, and benefits from, each of the other projects and cores. Successful completion of the proposed work will provide critical insights into RAS signaling and form a foundation for bringing targeted therapy for KRAS mutant lung cancer into the clinical arena.

Public Health Relevance

Although KRAS is the most frequently mutated oncogene in human lung cancer and represents a compelling therapeutic target, lung cancer patients harboring KRAS mutant cancers are currently treated with ineffective and toxic chemotherapies. This proposal uses optimized genetic and modeling platforms to reveal mechanisms of signaling plasticity and immune surveillance following treatment with RAS network inhibitors with the goal of identifying molecular targeted and/or immune oncology agents that could be used in combination to effectively treat KRAS mutant lung cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA129243-11
Application #
9417595
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-13
Budget End
2019-08-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Yu, Helena A; Perez, Leslie; Chang, Qing et al. (2017) A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. J Thorac Oncol 12:102-109
Ichihara, Eiki; Westover, David; Meador, Catherine B et al. (2017) SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res 77:2990-3000
Yaeger, Rona; Yao, Zhan; Hyman, David M et al. (2017) Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Res 77:6513-6523
Weigelt, Britta; Comino-Méndez, Iñaki; de Bruijn, Ino et al. (2017) Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res 23:6708-6720
Pal, Debjani; Pertot, Anja; Shirole, Nitin H et al. (2017) TGF-? reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells. Elife 6:
Yu, H A; Sima, C; Feldman, D et al. (2017) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol 28:278-284
Boire, Adrienne; Zou, Yilong; Shieh, Jason et al. (2017) Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. Cell 168:1101-1113.e13
Nieto, Patricia; Ambrogio, Chiara; Esteban-Burgos, Laura et al. (2017) A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature 548:239-243
Yao, Zhan; Yaeger, Rona; Rodrik-Outmezguine, Vanessa S et al. (2017) Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548:234-238
Drilon, Alexander; Somwar, Romel; Wagner, Jacob P et al. (2016) A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clin Cancer Res 22:2351-8

Showing the most recent 10 out of 168 publications